ALK Gene Mutation
Also known as: Anaplastic lymphoma kinase gene mutation
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB11595 | Atezolizumab | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. |
| DB14707 | Cemiplimab | A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. |
| DB11714 | Durvalumab | An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. |
| DB06186 | Ipilimumab | A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. |
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB11771 | Tremelimumab | An anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB11363 | Alectinib | 1 / 2 | Recruiting | 1 |
| DB00112 | Bevacizumab | 2 | Not Yet Recruiting | 1 |
| DB12267 | Brigatinib | 2 | Recruiting | 1 |
| DB12267 | Brigatinib | 2 | Withdrawn | 1 |
| DB00958 | Carboplatin | 2 | Recruiting | 1 |
| DB09037 | Pembrolizumab | 2 | Active Not Recruiting | 1 |
| DB09037 | Pembrolizumab | 2 | Not Yet Recruiting | 1 |
| DB00642 | Pemetrexed | 2 | Recruiting | 1 |
| DB14797 | SEphB4-HSA | 2 | Active Not Recruiting | 1 |
| DB11363 | Alectinib | Not Available | Enrolling by Invitation | 1 |